ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
82.40
+0.22 (0.27%)
At close: Dec 26, 2025, 4:00 PM EST
82.41
+0.01 (0.01%)
After-hours: Dec 26, 2025, 5:24 PM EST
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover ANI Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $105.83, which forecasts a 28.43% increase in the stock price over the next year. The lowest target is $90 and the highest is $121.
Price Target: $105.83 (+28.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ANI Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 4 | 4 | 3 | 3 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 8 | 8 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $100 | Buy | Initiates | $100 | +21.36% | Dec 9, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $114 → $115 | Strong Buy | Maintains | $114 → $115 | +39.56% | Nov 10, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $77 → $90 | Hold | Maintains | $77 → $90 | +9.22% | Oct 9, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $95 → $115 | Buy | Maintains | $95 → $115 | +39.56% | Sep 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $93 → $121 | Strong Buy | Maintains | $93 → $121 | +46.84% | Sep 17, 2025 |
Financial Forecast
Revenue This Year
885.10M
from 614.38M
Increased by 44.06%
Revenue Next Year
965.33M
from 885.10M
Increased by 9.06%
EPS This Year
7.65
from -1.04
EPS Next Year
8.56
from 7.65
Increased by 11.83%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 922.4M | 1.1B | ||||
| Avg | 885.1M | 965.3M | ||||
| Low | 836.1M | 894.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 50.1% | 19.4% | ||||
| Avg | 44.1% | 9.1% | ||||
| Low | 36.1% | 1.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 8.03 | 10.21 | ||||
| Avg | 7.65 | 8.56 | ||||
| Low | 7.02 | 7.38 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 33.4% | ||||
| Avg | - | 11.8% | ||||
| Low | - | -3.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.